Treatment of Del17p and/or Aberrant TP53 Chronic Lymphocytic Leukemia in the Era of Novel Therapies.
Document Type
Journal Article
Publication Date
5-19-2017
Journal
Hematol/Oncology Stem Cell Therapy
DOI
10.1016/j.hemonc.2017.04.002
APA Citation
Rafei, H., & Kharfan-Dabaja, M. (2017). Treatment of Del17p and/or Aberrant TP53 Chronic Lymphocytic Leukemia in the Era of Novel Therapies.. Hematol/Oncology Stem Cell Therapy, (). http://dx.doi.org/10.1016/j.hemonc.2017.04.002
Peer Reviewed
1
